AVS is an early-stage medical device company developing the PULSE IVL System, a balloon-based pulsatile intravascular lithotripsy (PIVL) platform to treat severely calcified arterial disease. The device uses pressure waves in frequent bursts to gently shatter calcium and expand narrowed vessels through a single device. AVS completed a first-in-human POWER PAD I feasibility trial, enrolling patients and collecting positive 30-day follow-up in September 2022. The company plans to continue peripheral clinical trials and advance preclinical work toward an expanded coronary indication with the goal of U.S. approval for both applications. AVS closed an additional $8.8 million to bring its Series B to $28.8 million, funding that will support those clinical and preclinical efforts. The company was founded in 2018 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D. AVS is developing the PULSE IVL System, a balloon-based pulsatile intravascular lithotripsy platform that uses pressure waves in frequent bursts to shatter vascular calcium and expand calcified arteries with a single device. The company is advancing a peripheral PIVL device toward clinical trials and is conducting preclinical development on a coronary PIVL device. Early clinical work includes the POWER PAD I first-in-human study, which reported enrollment, successful treatment, and positive 30-day follow-up with patients noting reduced leg pain and improved walking ability. AVS was founded in 2018 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D., and the company is referenced from Boston. The PULSE Peripheral IVL System remains in development and is not yet cleared for commercial distribution. Management has signaled plans to accelerate trial timelines and development activities with new funding.

Total raised

$29M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2023